CAS 152-62-5|Dydrogesterone
Introduction：Basic information about CAS 152-62-5|Dydrogesterone, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | Dydrogesterone | ||
|---|---|---|---|
| CAS Number | 152-62-5 | Molecular Weight | 312.446 |
| Density | 1.1±0.1 g/cm3 | Boiling Point | 462.8±45.0 °C at 760 mmHg |
| Molecular Formula | C21H28O2 | Melting Point | 168-173°C |
| MSDS | / | Flash Point | 172.2±25.7 °C |
Names
| Name | dydrogesterone |
|---|---|
| Synonym | More Synonyms |
Dydrogesterone BiologicalActivity
| Description | Dydrogesterone(Duphaston) is a potent, orally active progestogen indicated in a wide variety of gynaecological conditions related to progesterone deficiency.IC50 value:Target: Progesterone ReceptorDydrogesterone is a potent, orally active progestogen indicated in a wide variety of gynaecological conditions related to progesterone deficiency. Although similar in molecular structure and pharmacological effects to endogenous progesterone. It is orally active at far lower doses. Its freedom from estrogenic, androgenic, anabolic, corticoid and other undesirable hormonal effects gives it additional benefits over most other synthetic progestogens.Dydrogesterone has also been registered as hormone replacement therapy (HRT) to counteract the negative effects of unopposed estrogen on the endometrium in women with an intact uterus. Dydrogesterone is relatively safe and well tolerated, and does not exhibit the androgenic side effects that are common with some other progestins, like medroxyprogesterone. |
|---|---|
| Related Catalog | Signaling Pathways >>Others >>Progesterone ReceptorResearch Areas >>Endocrinology |
| References | [1]. Dydrogesterone, From Wikipedia, the free encyclopedia |
Chemical & Physical Properties
| Density | 1.1±0.1 g/cm3 |
|---|---|
| Boiling Point | 462.8±45.0 °C at 760 mmHg |
| Melting Point | 168-173°C |
| Molecular Formula | C21H28O2 |
| Molecular Weight | 312.446 |
| Flash Point | 172.2±25.7 °C |
| Exact Mass | 312.208923 |
| PSA | 34.14000 |
| LogP | 3.58 |
| Vapour Pressure | 0.0±1.1 mmHg at 25°C |
| Index of Refraction | 1.557 |
| InChIKey | JGMOKGBVKVMRFX-HQZYFCCVSA-N |
| SMILES | CC(=O)C1CCC2C3C=CC4=CC(=O)CCC4(C)C3CCC12C |
| Storage condition | Refrigerator |
Toxicological Information
CHEMICAL IDENTIFICATION |
ACUTE TOXICITY DATA - TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Rodent - rat
- DOSE/DURATION :
- >4600 mg/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- REFERENCE :
- NIIRDN Drugs in Japan (Ethical Drugs). (Yakugyo Jiho Co., Ltd., Tokyo, Japan) Volume(issue)/page/year: 6,324,1982
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- >7200 mg/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- REFERENCE :
- NIIRDN Drugs in Japan (Ethical Drugs). (Yakugyo Jiho Co., Ltd., Tokyo, Japan) Volume(issue)/page/year: 6,324,1982 ** REPRODUCTIVE DATA **
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Subcutaneous
- DOSE :
- 70 mg/kg
- SEX/DURATION :
- female 14 day(s) pre-mating
- TOXIC EFFECTS :
- Reproductive - Maternal Effects - ovaries, fallopian tubes Reproductive - Fertility - other measures of fertility
- REFERENCE :
- CCPTAY Contraception. (Geron-X, Inc., POB 1108, Los Altos, CA 94022) V.1- 1970- Volume(issue)/page/year: 5,57,1972
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Oral
- DOSE :
- 1600 mg/kg
- SEX/DURATION :
- female 13-28 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Specific Developmental Abnormalities - urogenital system
- REFERENCE :
- ACENA7 Acta Endocrinologica (Copenhagen). (Periodica, Skolegade 12 E, DK-2500 Valby, Denmark) V.1- 1948- Volume(issue)/page/year: 43,539,1963
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Subcutaneous
- DOSE :
- 40 mg/kg
- SEX/DURATION :
- female 13-28 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Specific Developmental Abnormalities - urogenital system
- REFERENCE :
- ACENA7 Acta Endocrinologica (Copenhagen). (Periodica, Skolegade 12 E, DK-2500 Valby, Denmark) V.1- 1948- Volume(issue)/page/year: 43,539,1963
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Subcutaneous
- DOSE :
- 1500 ug/kg
- SEX/DURATION :
- female 2 day(s) pre-mating female 1 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Fertility - pre-implantation mortality (e.g. reduction in number of implants per female; total number of implants per corpora lutea)
- REFERENCE :
- AJOGAH American Journal of Obstetrics and Gynecology. (C.V. Mosby Co., 11830 Westline Industrial Dr., St. Louis, MO 63146) V.1- 1920- Volume(issue)/page/year: 117,167,1973
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Subcutaneous
- DOSE :
- 40 mg/kg
- SEX/DURATION :
- female 10 day(s) pre-mating
- TOXIC EFFECTS :
- Reproductive - Fertility - female fertility index (e.g. # females pregnant per # sperm positive females; # females pregnant per # females mated)
- REFERENCE :
- FESTAS Fertility and Sterility. (American Fertility Soc., 608 13th Ave. S, Birmingham, AL 35282) V.1- 1950- Volume(issue)/page/year: 23,196,1972
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Parenteral
- DOSE :
- 2400 ug/kg
- SEX/DURATION :
- female 3 day(s) pre-mating
- TOXIC EFFECTS :
- Reproductive - Fertility - mating performance (e.g. # sperm positive females per # females mated; # copulations per # estrus cycles)
- REFERENCE :
- JRPFA4 Journal of Reproduction and Fertility. (Biochemical Soc. Book Depot, POB 32, Commerce Way, Colchester, Essex CO2 8HP, UK) V.1- 1960- Volume(issue)/page/year: 37,269,1974 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - X9388 No. of Facilities: 27 (estimated) No. of Industries: 1 No. of Occupations: 1 No. of Employees: 191 (estimated) No. of Female Employees: 82 (estimated)
Safety Information
| Safety Phrases | S26-S37/39 |
|---|---|
| RIDADR | 3276 |
| WGK Germany | 3 |
| Packaging Group | III |
| Hazard Class | 6.1 |
Articles37
More Articles| Coagulation and fibrynolitic parameters in women and the effects of hormone therapy; comparison of transdermal and oral administration. Gynecol. Endocrinol. 29(2) , 165-8, (2013) It is established that hormone therapy (HT) is related with significant increased prothrombotic risk factor. The aim of our study was to assess the effects of oral hormone therapy (o-HT) and transderm... | |
| Oral estradiol and dydrogesterone combination therapy in postmenopausal women: review of efficacy and safety. Maturitas 76(1) , 10-21, (2013) HRT is known to be effective for the relief of menopausal symptoms and prevention of osteoporosis. HRT should be tailored to the woman, enhancing the beneficial effects of the treatment while minimizi... | |
| Hormone replacement therapy regimens in chemotherapy-induced premature ovarian failure and the subsequent correction of hormone levels. Neuro Endocrinol. Lett. 33(7) , 697-702, (2012) Premature ovarian failure (POF) is a consequence of gonadotoxic chemoradiotherapy given in antyneoplasia treatment. In young women it will correlate with menopausal symptoms which tend to appear due t... |
Synonyms
| Dydrogesterone |
| D6-Retroprogesterone |
| δ6-Retroprogesterone |
| 9β,10α-Pregna-4,6-diene-3,20-dione (8CI) |
| 9b,10a-Pregna-4,6-diene-3,20-dione |
| (8S,9R,10S,13S,14S,17S)-17-acetyl-10,13-dimethyl-1,2,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-one |
| (9β,10α)-Pregna-4,6-diene-3,20-dione |
| EINECS 205-806-8 |
| 6-Dehydro-9b,10a-progesterone |
| MFCD00867864 |
| 10a-Isopregnenone |
| 6-Dehydroretroprogesterone |
| 6-Dehydro-9β,10α-progesterone |
| (9b,10a)-Pregna-4,6-diene-3,20-dione |
| Pregna-4,6-diene-3,20-dione, (9β,10α)- |
